| アブストラクト | Antibody-drug conjugates (ADCs) are among the fastest-growing classes of anticancer drugs, making it crucial to evaluate their potential for causing peripheral neuropathy. We analyzed data from the FAERS database (January 1, 2014, to June 30, 2023) using disproportionality and Bayesian methods. We identified 3076 cases of ADC-associated peripheral neuropathy. Our study revealed significant signals for all ADCs (ROR 1.82, 95% CI 1.76-1.89). ADCs with tubulin-binding payloads showed significant peripheral neuropathy signals (ROR 2.31, 95% CI 2.23-2.40), whereas those with DNA-targeting (ROR 0.48, 95% CI 0.39-0.59) and topoisomerase 1 inhibitor (ROR 0.56, 95% CI 0.48-0.66) payloads exhibited non-significant signals. Signals for peripheral sensory neuropathy were 4.83, 2.44, 2.74, and 2.21 (calculated based on IC(025)) for brentuximab vedotin, trastuzumab emtansine, enfortumab vedotin, and polatuzumab vedotin, while signals for peripheral motor neuropathy were 5.31, 0.34, 2.27, and 0.03, respectively. The median time to onset for all ADCs was 127 days (interquartile range 40-457). Tisotumab vedotin had the highest hospitalization rate at 26.67%, followed by brentuximab vedotin at 25.5%. Trastuzumab emtansine had the highest mortality rate ,with 80 deaths (11.96%) among 669 cases. Based on FAERS database, only ADCs with tubulin-binding payloads exhibited significant peripheral neuropathy signals. Brentuximab vedotin and enfortumab vedotin showed similar profiles for peripheral sensory neuropathy and motor neuropathy. Given the delayed time to onset and potentially poor outcomes, ADC-related peripheral neuropathy warrants significant attention. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| 投稿日 | 2024/9/14 |
|---|
| 投稿者 | Chen, Yuheng; Ren, Xiayang; Dai, Yuanyuan; Wang, Yanfeng |
|---|
| 組織名 | Party Committee Office, National Cancer Center, National Clinical Research Center;for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union;Medical College, Beijing, China.;Department of Pharmacy, National Cancer Center, National Clinical Research Center;Department of Comprehensive Oncology, National Cancer Center, National Clinical;Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences;and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District,;Beijing, 100021, China. wangyf@cicams.ac.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39271716/ |
|---|
